Ketamine Versus Placebo for Treatment Resistant Major Depressive Disorder
| Status: | Recruiting |
|---|---|
| Conditions: | Depression, Major Depression Disorder (MDD) |
| Therapuetic Areas: | Psychiatry / Psychology, Pulmonary / Respiratory Diseases |
| Healthy: | No |
| Age Range: | 18 - 65 |
| Updated: | 4/2/2016 |
| Start Date: | January 2013 |
| End Date: | October 2016 |
| Contact: | Cristina Cusin, M.D. |
| Email: | ccusin@mgh.harvard.edu |
| Phone: | 1-617-726-6421 |
Randomized, Double-blind Ketamine Augmentation in Chronically Suicidal, Treatment-resistant Major Depression
Ketamine infusions resulted in an acute reduction in global depression scores and in
severity of suicidal ideation. The investigators therefore plan to investigate the
feasibility and efficacy of repeated intravenous administration of ketamine in severely
depressed, treatment resistant patients. The results of the study could lead to development
of new strategies for treating depression.
severity of suicidal ideation. The investigators therefore plan to investigate the
feasibility and efficacy of repeated intravenous administration of ketamine in severely
depressed, treatment resistant patients. The results of the study could lead to development
of new strategies for treating depression.
Inclusion Criteria:
- Outpatient with sever treatment resistant depression
- Currently depressed
- Currently under regular psychiatric care
- On an aggressive antidepressant regimen, stable for 4 weeks.
Exclusion Criteria:
- No history of other major psychiatric illness, including bipolar
- No history of psychosis
- No history of drug abuse
- No major medical illness or unstable medical problem
We found this trial at
1
site
Click here to add this to my saved trials
